219 related articles for article (PubMed ID: 34555758)
1. Mutations in the John Cunningham virus VP1 gene could predispose to the development of progressive multifocal leukoencephalopathy in multiple sclerosis patients undergoing treatment with natalizumab.
Flores J; Anguiano O; Rivas-Alonso V; González-Conchillos H; Pérez-Saldivar M; Sotelo J; Magaña-Maldonado R; Quiñones S; Corona T; Olivares H; Hernández-González O; Martínez-Palomo A; Treviño I; Ordoñez G
Mult Scler Relat Disord; 2021 Nov; 56():103266. PubMed ID: 34555758
[TBL] [Abstract][Full Text] [Related]
2. Association of Progressive Multifocal Leukoencephalopathy Lesion Volume With JC Virus Polymerase Chain Reaction Results in Cerebrospinal Fluid of Natalizumab-Treated Patients With Multiple Sclerosis.
Wijburg MT; Kleerekooper I; Lissenberg-Witte BI; de Vos M; Warnke C; Uitdehaag BMJ; Barkhof F; Killestein J; Wattjes MP
JAMA Neurol; 2018 Jul; 75(7):827-833. PubMed ID: 29532061
[TBL] [Abstract][Full Text] [Related]
3. Comparison of qPCR with ddPCR for the Quantification of JC Polyomavirus in CSF from Patients with Progressive Multifocal Leukoencephalopathy.
Ngouth N; Monaco MC; Walker L; Corey S; Ikpeama I; Fahle G; Cortese I; Das S; Jacobson S
Viruses; 2022 Jun; 14(6):. PubMed ID: 35746716
[TBL] [Abstract][Full Text] [Related]
4. Monitoring the John Cunningham virus throughout natalizumab treatment in multiple sclerosis patients.
Domínguez-Mozo MI; García-Montojo M; Arias-Leal A; García-Martínez Á; Santiago JL; Casanova I; Galán V; Arroyo R; Fernández-Arquero M; Alvarez-Lafuente R
Eur J Neurol; 2016 Jan; 23(1):182-9. PubMed ID: 26498276
[TBL] [Abstract][Full Text] [Related]
5. Cerebrospinal fluid JC virus antibody index for diagnosis of natalizumab-associated progressive multifocal leukoencephalopathy.
Warnke C; von Geldern G; Markwerth P; Dehmel T; Hoepner R; Gold R; Pawlita M; Kümpfel T; Mäurer M; Stangel M; Wegner F; Hohlfeld R; Straeten V; Limmroth V; Weber T; Hermsen D; Kleinschnitz C; Hartung HP; Wattjes MP; Svenningson A; Major E; Olsson T; Kieseier BC; Adams O
Ann Neurol; 2014 Dec; 76(6):792-801. PubMed ID: 24729444
[TBL] [Abstract][Full Text] [Related]
6. Sequencing and analysis of JC virus DNA from natalizumab-treated PML patients.
Reid CE; Li H; Sur G; Carmillo P; Bushnell S; Tizard R; McAuliffe M; Tonkin C; Simon K; Goelz S; Cinque P; Gorelik L; Carulli JP
J Infect Dis; 2011 Jul; 204(2):237-44. PubMed ID: 21673034
[TBL] [Abstract][Full Text] [Related]
7. Atypical Multiple Sclerosis Lesions or Progressive Multifocal Leukoencephalopathy Lesions: That Is the Question.
De Mercanti SF; Gned D; Matta M; Iudicello M; Franchin E; Clerico M
J Investig Med High Impact Case Rep; 2020; 8():2324709620939802. PubMed ID: 32646245
[TBL] [Abstract][Full Text] [Related]
8. Course of neuropsychological impairment during natalizumab-associated progressive multifocal leukoencephalopathy.
Kinner M; Prehn C; Schneider R; Schroeder C; Kolb E; Gold R; Hoepner R; Chan A
Eur J Neurol; 2021 Mar; 28(3):921-927. PubMed ID: 33085811
[TBL] [Abstract][Full Text] [Related]
9. Natalizumab-Related Progressive Multifocal Leukoencephalopathy in Multiple Sclerosis: Findings from an Italian Independent Registry.
Prosperini L; de Rossi N; Scarpazza C; Moiola L; Cosottini M; Gerevini S; Capra R;
PLoS One; 2016; 11(12):e0168376. PubMed ID: 27997580
[TBL] [Abstract][Full Text] [Related]
10. Synthetic antibodies and peptides recognizing progressive multifocal leukoencephalopathy-specific point mutations in polyomavirus JC capsid viral protein 1.
Chen G; Gorelik L; Simon KJ; Pavlenco A; Cheung A; Brickelmaier M; Chen LL; Jin P; Weinreb PH; Sidhu SS
MAbs; 2015; 7(4):681-92. PubMed ID: 25879139
[TBL] [Abstract][Full Text] [Related]
11. Which is the best PML risk stratification strategy in natalizumab-treated patients affected by multiple sclerosis?
Prezioso C; Zingaropoli MA; Iannetta M; Rodio DM; Altieri M; Conte A; Vullo V; Ciardi MR; Palamara AT; Pietropaolo V
Mult Scler Relat Disord; 2020 Jun; 41():102008. PubMed ID: 32087593
[TBL] [Abstract][Full Text] [Related]
12. Association of B-cell activating factor gene variants with serum anti-JCV antibody positivity in male patients with multiple sclerosis under natalizumab treatment: Implications for progressive multifocal leukoencephalopathy risk stratification.
Skarlis C; Papadopoulos V; Raftopoulou S; Mavragani CP; Evangelopoulos ME
J Neurol Sci; 2024 Jun; 461():123046. PubMed ID: 38761670
[TBL] [Abstract][Full Text] [Related]
13. Successful pregnancy after natalizumab-associated progressive multifocal leukoencephalopathy in a patient with multiple sclerosis.
Pitarokoili K; Hellwig K; Lukas C; Gold R
Mult Scler; 2017 Mar; 23(3):483-486. PubMed ID: 28260421
[TBL] [Abstract][Full Text] [Related]
14. Progressive multifocal leukoencephalopathy in two natalizumab-treated stepsisters: An intriguing coincidence.
Bacchetta F; Mathias A; Schluep M; Du Pasquier R
Mult Scler; 2017 Feb; 23(2):300-303. PubMed ID: 28165319
[TBL] [Abstract][Full Text] [Related]
15. Risk Assessment of Progressive Multifocal Leukoencephalopathy in Multiple Sclerosis Patients during 1 Year of Ocrelizumab Treatment.
Prezioso C; Grimaldi A; Landi D; Nicoletti CG; Brazzini G; Piacentini F; Passerini S; Limongi D; Ciotti M; Palamara AT; Marfia GA; Pietropaolo V
Viruses; 2021 Aug; 13(9):. PubMed ID: 34578264
[TBL] [Abstract][Full Text] [Related]
16. Lipid-specific immunoglobulin M bands in cerebrospinal fluid are associated with a reduced risk of developing progressive multifocal leukoencephalopathy during treatment with natalizumab.
Villar LM; Costa-Frossard L; Masterman T; Fernandez O; Montalban X; Casanova B; Izquierdo G; Coret F; Tumani H; Saiz A; Arroyo R; Fink K; Leyva L; Espejo C; Simó-Castelló M; García-Sánchez MI; Lauda F; Llufriú S; Álvarez-Lafuente R; Olascoaga J; Prada A; Oterino A; de Andrés C; Tintoré M; Ramió-Torrentà L; Rodríguez-Martín E; Picón C; Comabella M; Quintana E; Agüera E; Díaz S; Fernandez-Bolaños R; García-Merino JA; Landete L; Menéndez-González M; Navarro L; Pérez D; Sánchez-López F; Serrano-Castro PJ; Tuñón A; Espiño M; Muriel A; Bar-Or A; Álvarez-Cermeño JC
Ann Neurol; 2015 Mar; 77(3):447-57. PubMed ID: 25581547
[TBL] [Abstract][Full Text] [Related]
17. Radiological abnormalities in progressive multifocal leukoencephalopathy: Identifying typical and atypical imaging patterns for early diagnosis and differential considerations.
Soni N; Ora M; Mangla R; Singh R; Ellika S; Agarwal A; Meyers SP; Bathla G
Mult Scler Relat Disord; 2023 Sep; 77():104830. PubMed ID: 37418930
[TBL] [Abstract][Full Text] [Related]
18. Longitudinal JCV serology in multiple sclerosis patients preceding natalizumab-associated progressive multifocal leukoencephalopathy.
Vennegoor A; van Rossum JA; Polman CH; Wattjes MP; Killestein J
Mult Scler; 2015 Oct; 21(12):1600-3. PubMed ID: 25662344
[TBL] [Abstract][Full Text] [Related]
19. Reduction of the risk of PML in natalizumab treated MS patients in Sweden: An effect of improved PML risk surveillance.
Kågström S; Fält A; Berglund A; Piehl F; Olsson T; Lycke J
Mult Scler Relat Disord; 2021 May; 50():102842. PubMed ID: 33610957
[TBL] [Abstract][Full Text] [Related]
20. Risk of natalizumab-associated progressive multifocal leukoencephalopathy.
Bloomgren G; Richman S; Hotermans C; Subramanyam M; Goelz S; Natarajan A; Lee S; Plavina T; Scanlon JV; Sandrock A; Bozic C
N Engl J Med; 2012 May; 366(20):1870-80. PubMed ID: 22591293
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
